Provided by Tiger Trade Technology Pte. Ltd.

Quince Therapeutics, Inc.

33.75
+1.253.85%
Post-market: 33.750.00000.00%19:30 EDT
Volume:27.17K
Turnover:925.37K
Market Cap:34.33M
PE:-0.37
High:35.34
Open:32.91
Low:31.85
Close:32.50
52wk High:909.98
52wk Low:15.10
Shares:1.02M
Float Shares:679.70K
Volume Ratio:2.16
T/O Rate:4.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-90.9250
EPS(LYR):-335.2669
ROE:-153.84%
ROA:-31.51%
PB:-0.97
PE(LYR):-0.10

Loading ...

Quince Therapeutics trading halted, news pending

TIPRANKS
·
Apr 11

Quince Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 11

Quince FY25 net loss widens 48% to $84 million

Reuters
·
Apr 11

U.S. Earnings Preview: After Market Close April 10

Dow Jones
·
Apr 11

NASD Most Active Issues

Dow Jones
·
Apr 10

NASD Most Active Issues

Dow Jones
·
Apr 08

Quince Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Apr 03

Top News Today/Canada: Goods-Trade Deficit Widens, Surplus With U.S. Narrows

Dow Jones
·
Apr 03

Quince Therapeutics delays annual 10-K filing, cites added time for accounting procedures

Reuters
·
Apr 02

NASD Most Active Issues

Dow Jones
·
Mar 31

BRIEF-Quince Therapeutics Settles Approximately $16.4 Million Of Debt

Reuters
·
Mar 30

Quince Therapeutics - Settles Eib Loan Obligations for $5.5 Mln - SEC Filing

THOMSON REUTERS
·
Mar 30

Quince Therapeutics settles $16 million EIB debt in restructuring milestone

Reuters
·
Mar 30

Quince Therapeutics Settles Approximately $16.4 Million of Debt

THOMSON REUTERS
·
Mar 30

U.S. Earnings Preview: After Market Close March 27

Dow Jones
·
Mar 28

Nasdaq flags Quince Therapeutics for sub-$1 bid price and sub-USD 50 million market value

Reuters
·
Mar 21

U.S. Earnings Preview: After Market Close March 20

Dow Jones
·
Mar 21

Quince Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Mar 20

NASD Most Active Issues

Dow Jones
·
Mar 12

ADVISORY-Alert incorrectly tagged to Quince Therapeutics withdrawn

Reuters
·
Mar 11